Successful treatment of diffuse large B-cell lymphoma with clarithromycin and prednisolone

Korean Journal of Hematology

Volumn 47, Issue 4, 2012, Pages 293-297

  Ohe, Masash ^a   Hashino, Satoshi ^b   Hattori, Atsuo ^a  

^a Hokkaido Social Insurance Hospital   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Clarithromycin; Diffuse large B cell lymphoma; Prednisolone

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; FLUORODEOXYGLUCOSE; INTERLEUKIN 2 RECEPTOR; LACTATE DEHYDROGENASE; LEVOFLOXACIN; PREDNISOLONE; TUBERCULOSTATIC AGENT;

AGED; ARTICLE; ATYPICAL MYCOBACTERIOSIS; AXILLARY LYMPH NODE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CASE REPORT; CERVICAL SPINE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LUNG INFECTION; LYMPH NODE BIOPSY; LYMPHADENOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; SIDE EFFECT; TASTE; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

EID: 84874056848     PISSN: 17387949     EISSN: 20929129     Source Type: Journal    
DOI: 10.5045/kjh.2012.47.4.293     Document Type: Article

References (15)

1. Govi S, Dognini GP, Licata G, et al. Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial. Br J Haematol 2010;150:226-9.
2. Ishimatsu Y, Mukae H, Matsumoto K, et al. Two cases with pulmonary mucosa-associated lymphoid tissue lymphoma successfully treated with clarithromycin. Chest 2010;138:730-3.
3. Ohe M, Hashino S. A case of follicular B-cell lymphoma treated using clarithromycin. Korean J Hematol 2011;46:203-6.
4. Niesvizky R, Jayabalan DS, Christos PJ, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008;111:1101-9.
5. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-94.
6. Matsumoto A, Enomoto T, Muroya Y, et al. Pulmonary nontuberculous mycobacteriosis (Mycobacterium intracellulare) with cavities developing in a non-small cell lung cancer patient during chemotherapy. Nihon Kokyuki Gakkai Zasshi 2010;48: 609-13.
7. Nicholas A, Pavlidis MD, Menelaus N, et al. Serum soluble interleukin-2 receptors in B-cell lymphoproliferative malignancies. Med Pediatr Oncol 1992;20:26-31.
8. Ohara T, Morishita T, Suzuki H, Masaoka T, Ishii H, Hibi T. Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB/c mice. Anticancer Res 2004;24:3723-30.
9. Chen Y, Han T, Iqbal J, et al. Diffuse large B-cell lymphoma in Chinese patients: immunophenotypic and cytogenetic analyses of 124 cases. Am J Clin Pathol 2010;133:305-13.
10. Iqbal J, Neppalli VT, Wright G, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006;24:961-8.
11. Heckman CA, Mehew JW, Boxer LM. NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene 2002;21:3898-908.
12. Bavi P, Uddin S, Bu R, et al. The biological and clinical impact of inhibition of NF-?B-initiated apoptosis in diffuse large B cell lymphoma (DLBCL). J Pathol 2011;224:355-66.
13. Ichiyama T, Nishikawa M, Yoshitomi T, et al. Clarithromycin inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob Agents Chemother 2001;45:44-7.
14. Ploner C, Schmidt S, Presul E, et al. Glucocorticoid-induced apoptosis and glucocorticoid resistance in acute lymphoblastic leukemia. J Steroid Biochem Mol Biol 2005;93:153-60.
15. Weller M. Glucocorticoid treatment of primary CNS lymphoma. J Neurooncol 1999;43:237-9.